Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Trend
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Price Action
Support & Resistance Levels
Volume Analysis
Recent MA Crossovers
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹4,358.1 Cr | ₹3,910.1 Cr | ₹4,262.5 Cr | ₹4,173 Cr |
| Net Profit | ₹344.5 Cr | ₹31.4 Cr | ₹84.5 Cr | ₹143.8 Cr |
| EPS | — | ₹0.26 | ₹0.66 | ₹1.08 |
| Operating Profit | ₹1,125.8 Cr | ₹828.6 Cr | ₹916.5 Cr | ₹657.4 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 04 Jul 2025 | Dividend - Rs 0.50 Per Share | DIVIDEND |
| 05 Jul 2024 | Dividend - Re 0.50 Per Share | DIVIDEND |
| 07 Jul 2023 | Dividend - Rs 1.50 Per Share | DIVIDEND |
| 30 Jun 2022 | Dividend - Rs 0.50 Per Share | DIVIDEND |
| 18 Jul 2019 | Dividend - Rs 0.50 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for BIOCON
View All
Insider trading: Supreme Court upholds SAT clearance to Biocon MD
The Supreme Court has backed a tribunal's decision, clearing Biocon's managing director, Shreehas P Tambe, of insider trading allegations from 2017. The Securities and Exchange Board of India's appeal was rejected. Tambe was accused of trading Biocon shares while possessing unpublished price-sensitive information.
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.
Gland Pharma to Biocon: Pharma stocks rally up to 27% in a month: Can they shield portfolio from US-Iran war-led risks?
The Nifty Pharma index has surged nearly 11% over the past month, significantly outperforming the Nifty 50, which declined 3.6% during the same period. On a year-to-date (YTD) basis, the Nifty Pharma index has gained 9.4%, while the benchmark Nifty 50 has fallen by an equal margin.